PATRICK CRAIG WalshShow email address
The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA | Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
PATRICK CRAIG Walsh:Expert Impact
Concepts for whichPATRICK CRAIG Walshhas direct influence:Prostate cancer,Radical prostatectomy,Specific antigen,Pathological stage,Prostate specific,Biochemical recurrence,Gleason score,Androgen receptors.
PATRICK CRAIG Walsh:KOL impact
Concepts related to the work of other authors for whichfor which PATRICK CRAIG Walsh has influence:Prostate cancer,Specific antigen,Active surveillance,Gleason score,Benign prostatic hyperplasia,Biochemical recurrence,Prostatic neoplasms.
KOL Resume for PATRICK CRAIG Walsh
The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Urology, Brady Urological Institute, Johns Hopkins University, Baltimore, MD.
Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
The Johns Hopkins University School of Medicine, Baltimore, MD;
James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, USA
James Buchanan Brady Urological Institute, The Johns Hopkins Hospital and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, and Departments of Anatomy and Embryology, and Urology, University of Leiden, Leiden, The Netherlands.
Department of Urology The Johns Hopkins Medical Institutions Baltimore MD USA
James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA
Duke University Medical Center, Durham, North Carolina (SJF)
Sungkyunkwan University Samsung Medical Center (BCJ), Seoul, South Korea
The Johns Hopkins Medical Institutions and The James Brady Buchannan Urological Institute Department of Urology Baltimore MD USA
James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Johns Hopkins Hospital, Department of Urology, 600 N. Wolfe St./Park 224, Baltimore, MD 21287‐2101.
Founders Professor of Urology, Perelman School of Medicine, University of Pennsylvania; Chief of Urology, Penn Medicine/University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Chairman, Glickman Urological Institute, Cleveland Clinic Foundation; Professor of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
Chairman and Waldbaum-Gardner Distinguished Professor, Smith Institute for Urology, Hofstra North Shore–LIJ School of Medicine, New York, New York
Affiliations of authors: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (CEJ, AMM, CM, EAP); James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD (EBH, MH, PCW, EAP); Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD (EAP)
The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland
Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA
Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD 21205;
Johns Hopkins University, Baltimore, MD, USA
Brady Urological Institute (Drs Trock, Han, Partin, and Walsh and Ms Humphreys) and Department of Radiation Oncology and Molecular Radiation Sciences (Dr DeWeese), Johns Hopkins University School of Medicine, Baltimore, Maryland
James Buchanan Brady Urological Institute, the Sidney Kimmel Comprehensive Cancer Center, the Department of Urology, Radiation Oncology and Molecular Radiation Sciences, and Johns Hopkins Medical Institutions, Baltimore, MD 21287-2101, USA.
Division of Urologic Surgery and Duke Prostate Center, Departments of Surgery and Pathology, Duke University School of Medicine Durham, NC
and The Biostatistics Core, University of Southern California, Keck School of Medicine at Childrens Hospital Los Angeles, Los Angeles, CA
Department of Surgery, Veterans Administration Medical Center Durham
Brady Urological Institute, Johns Hopkins Medical Institutions, 600 N. Wolfe St. Baltimore, Maryland 21287-2101
Department of Urology, The Johns Hopkins School of Medicine, Baltimore, Maryland
Johns Hopkins University School of Medicine, Baltimore, MD
From the Department of Pathology (TT, HA, JIE) and Department of Urology (DJH, BT, PCW, JIE), The Johns Hopkins Hospital, Baltimore, Maryland, and the Department of Pathology, Nagoya Daini Red Cross Hospital, Nagoya, Japan (TT)
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland
The James Buchanan Brady Urological Institute (Drs Freedland, Eisenberger, Walsh, and Partin and Mss Humphreys and Mangold) and the Departments of Urology (Drs Freedland, Eisenberger, Walsh, and Partin and Mss Humphreys and Mangold) and Oncology (Dr Eisenberger), The Johns Hopkins Medical Institutions, Baltimore, Md, and The Biostatistics Core, University of Southern California, Keck School of Medicine at Childrens Hospital Los Angeles, Los Angeles (Dr Dorey).
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
|location neurovascular bundles||#1|
|hypogonadotropic hypogonadism panhypopituitarism||#1|
|johns hopkins experience||#1|
|progression distant metastases||#1|
|failure astro criteria||#1|
|prostate size aging||#1|
|july psa recurrence||#1|
|24 months metastasis||#1|
|spironolactone castrated prostate||#1|
|prostatespecific antigen testosterone||#1|
|001 biochemical recurrence||#1|
|prostate squamous metaplasia||#1|
|cytosol human uterus||#1|
|established bph groups||#1|
|revised astro criterion—“nadir||#1|
|01 radical prostatectomy||#1|
|prostatic cancer mpsa||#1|
|placebo 3 odds||#1|
|stage cancer prepsa||#1|
|durable cancer control||#1|
|logrank analysis differences||#1|
|study 94 cases||#1|
|risk families age||#1|
|size periurethral zone||#1|
|tumors longer intervals||#1|
|t2b single stage||#1|
|excellent cancer control||#1|
|months androgen deprivation||#1|
|genetic studies gene||#1|
|probability undetectable psa||#1|
|nerves corpora cavernosa||#1|
|Sign-in to see all concepts, it's free!|
Prominent publications by PATRICK CRAIG Walsh
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy
[ PUBLICATION ]
OBJECTIVES: To determine the clinical significance of Gleason score 3+4 versus 4+3 on radical prostatectomy.
METHODS: Of 2390 men who underwent radical prostatectomy by a single surgeon, 570 had Gleason score 7 tumors without lymph node metastasis, seminal vesicle invasion, or tertiary Gleason pattern 5. Patients were evaluated for biochemical recurrence (prostate-specific antigen progression) and distant metastases.
RESULTS: Eighty percent of patients had Gleason score 3+4, 20% had 4+3. ...
|Known for Gleason Score | Radical Prostatectomy | 3 4 | Prognostic Significance | 7 Tumors|
Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy
[ PUBLICATION ]
CONTEXT: Biochemical disease recurrence after radical prostatectomy often prompts salvage radiotherapy, but no studies to date have had sufficient numbers of patients or follow-up to determine whether radiotherapy improves survival, and if so, the subgroup of men most likely to benefit.
OBJECTIVES: To quantify the relative improvement in prostate cancer-specific survival of salvage radiotherapy vs no therapy after biochemical recurrence following prostatectomy, and to identify subgroups ...
|Known for Salvage Radiotherapy | Specific Survival | Prostate Cancer | Biochemical Recurrence | Hormonal Therapy|
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
[ PUBLICATION ]
CONTEXT: The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.
OBJECTIVE: To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied.
DESIGN: Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech ...
|Known for Prostate Cancer | Percentage Free Psa | Benign Prostatic Disease | Specific Antigen | Unnecessary Biopsies|
Correlation of Clinical Stage, Serum Prostatic Acid Phosphatase and Preoperative Gleason Grade with Final Pathological Stage in 275 Patients with Clinically Localized Adenocarcinoma of the Prostate
[ PUBLICATION ]
The usefulness of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade in predicting final pathological stage in patients with adenocarcinoma of the prostate remains controversial. To determine the predictive value of these 3 preoperative variables we reviewed 275 patients with clinically localized disease who were treated between April 1982 and February 1986. All patients were examined preoperatively and subsequently were operated upon by 1 urologist. Serum ...
|Known for Gleason Grade | Clinical Stage | Acid Phosphatase | Capsular Penetration | Serum Prostatic|
No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer
[ PUBLICATION ]
BACKGROUND: Two genes responsible for hereditary breast cancer (BRCA1 and BRCA2) have been identified, and predisposing mutations identified. Several studies have provided evidence that germline mutations in BRCA1 and BRCA2 confer an increased risk of prostate cancer. Based on these findings, one might expect to find an increased frequency of mutations in these genes in family clusters of prostate cancer. The Ashkenazi Jewish population is unique in that it has an approximate 2% ...
|Known for Brca2 Mutations | Prostate Cancer | Brca1 Genes | Ashkenazi Jewish | Increased Frequency|
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The Gleason scoring system is a well-established predictor of pathological stage and oncological outcomes for men with prostate cancer. Modifications throughout the last few decades - most recently by the International Society of Urological Pathology (ISUP) in 2005 - have attempted to improve the correlation between biopsy and radical prostatectomy Gleason sum and better stratify patients to predict clinical outcomes. Based on ...
|Known for Gleason Grade | International Society | Positive Cores | Radical Prostatectomy Rp | Urological Pathology|
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate
[ PUBLICATION ]
METHODS: We identified 320 men with Gleason score 7 tumors on prostate biopsy treated with radical prostatectomy between 1991 and 2001 by a single surgeon. None of these patients had received neoadjuvant or adjuvant hormonal therapy or radiotherapy. The chi-square test and Kaplan-Meier method were used to ...
|Known for Gleason Pattern | Needle Biopsy | Radical Prostatectomy | Score 7 | Biochemical Recurrence|
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
[ PUBLICATION ]
OBJECTIVES: Various methods have been proposed to increase the specificity of prostate-specific antigen (PSA), including age-specific PSA reference ranges, PSA density (PSAD), and percent free PSA (%fPSA). In this multicenter study, we compared these methods for their utility in cancer detection and their ability to predict pathologic stage after radical prostatectomy in patients with clinically localized, Stage T1c cancer.
METHODS: Seven hundred seventy-three men (379 with prostate ...
|Known for Cancer Detection | Psa Density | Percent Free | Age Specific | Radical Prostatectomy|
Radical Prostatectomy for Impalpable Prostate Cancer: The Johns Hopkins Experience With Tumors Found on Transurethral Resection (Stages T1a and T1b) and on Needle Biopsy (Stage T1c)
[ PUBLICATION ]
We review the pathological findings of impalpable prostate cancer detected by transurethral resection (stages T1a and T1b) and needle biopsy (stage T1c). The short-term (4 years) and long-term (8 to 10 years) natural histories of untreated stage T1a prostate cancer are examined, as are options to follow patients expectantly. The findings on radical prostatectomy for stages T1a and T1b disease are reviewed and compared. Of the 64 cases of stage T1a disease 13 (20%) showed substantial ...
|Known for Needle Biopsy | Transurethral Resection | Stages T1a | Radical Prostatectomy | Prostate Cancer|
Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia
[ PUBLICATION ]
To evaluate the usefulness of serum prostate specific antigen in the preoperative staging of prostate cancer we examined tumor volume and differentiation, as well as benign prostatic hyperplasia volume to determine their influence on serum antigen levels. Serum prostate specific antigen was measured in 350 men with clinically localized prostate cancer and preoperatively in 72 men with documented benign prostatic hyperplasia. Although the mean antigen levels increased with advancing ...
|Known for Tumor Volume | Benign Hyperplasia | Prostate Specific | Pathological Stage | Antigen Levels|
Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer: A Multi-institutional Update
[ PUBLICATION ]
Objective. —To combine the clinical data from 3 academic institutions that serve as centers of excellence for the surgical treatment of clinically localized prostate cancer and develop a multi-institutional model combining serum prostate-specific antigen (PSA) level, clinical stage, and Gleason score to predict pathological stage for men with clinically localized prostate cancer.Design. —In this update, we have combined clinical and pathological data for a group of 4133 men treated by ...
|Known for Pathological Stage | Gleason Score | Localized Prostate Cancer | Seminal Vesicle Involvement | Nomograms Probability|
VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER
[ PUBLICATION ]
PURPOSE: The accurate prediction of pathological stage of prostate cancer using preoperative factors is a critical aspect of treatment. In 1997 Partin et al published tables predicting pathological stage using clinical stage, Gleason score and prostate specific antigen (PSA). We tested the validity of the Partin tables.
MATERIALS AND METHODS: From 1990 to 1996 inclusively 5,780 patients underwent bilateral pelvic lymphadenectomy and radical prostatectomy for prostate cancer at the Mayo ...
|Known for Pathological Stage | Partin Tables | Prostate Cancer | Neoplasms Roc | Gleason Score|